



71-9290

February 20, 2003

Mr. John D. Monninger
Section Chief
Licensing Section
Spent Fuel Project Office
Office of Nuclear Material Safety and Safeguards
Mail Stop: 13 D13
United States Nuclear Regulatory Commission
One White Flint North
11555 Rockville Pike
Rockville, MD
20852-2738

RE: Safety Analysis Report for the F-430/GC-40 Transport Package

Dear Mr. Monninger:

Please find attached the revised Safety Analysis Report for the F-430/GC40, which includes the modified tie-down system in Appendix 2.10.3. The tie-down system for the F-430 has been modified and now consists of a collar fitted around the F-430 at the time of shipment. The tie-down collar girdles the mid-section of the F-430 and includes four tie-down lugs. The tie-down collar is not a structural part of the package. The payload of the F-430 has been decrease to 1820 kg to compensate for the increase in weight due to the tie-down collar. The overall weight of the package has not changed and remains at 3175 kg. A complete revised Safety Analysis Report has been provided. It should be noted that this revised edition includes editorial changes as a result of questions received by the Canadian Nuclear Safety Commission. Changes relative to the USNRC approved revision are highlighted with change bars in the text.

Attached are five proprietary copies of MDS Nordion's Report "IN/TR 1608 F430 (2a), Safety Analysis Report for the F-430/GC-40 Transport Package" and one non-proprietary copy for the Public Document Room. In addition I have attached an affidavit to support MDS Nordion's request to withhold parts of the Safety Analysis Report IN/TR 1608 F430 from public disclosure. Parts of these sections have been deleted from the Safety Analysis Report, as they are specific to the design and fabrication of the F-430/GC-40 and would enable a third party to manufacture a similar transport package.

MMSS04

If you have any questions or require further information please feel free to contact me by telephone at (613) 592-3400 extension 2421 or by email at mcharette@mds.nordion.com.

Yours sincerely

A handwritten signature in black ink, appearing to read "Marc-André Charette". The signature is fluid and cursive, with a long horizontal stroke extending to the right.

Marc-André Charette
Regulatory Affairs Senior Associate
MDS Nordion

Attached: IN/TR 1608 F430 (2a), Affidavit

Copy to: Mike Krzaniak, Blair Menna, MDS Nordion

AFFIDAVIT

I, David McInnes, in my capacity as Vice President, Corporate Communications, having been duly authorized to apply for withholding from disclosure of proprietary information by and on behalf of MDS Nordion, a division of MDS (Canada) Inc., ("MDS Nordion"), do depose and say:


1. I, David McInnes, am the Vice President, Corporate Communications, of MDS Nordion.
2. The information contained in the MDS Nordion's, document IN/TR 1608 F430 (2a) is the property of MDS Nordion. These documents contain proprietary information related to the design of the F-430/GC-40 transport package.
3. MDS Nordion, has expended extensive funds and manpower in developing the aforementioned documents and any release for disclosure of such information to third parties would enable and assist third parties to use the information to fabricate and register a similar transport package without incurring any development costs. This could compromise MDS Nordion's, ability to compete in the marketplace. Therefore, MDS Nordion, submits that parts of the following MDS Nordion document, should be withheld from public disclosure.


MDS Nordion report No. IN/TR 1608 F430 (2a), "Safety Analysis Report F430/GC-40 Transport Package"

- Section 1.2, 1.3
- Figures 1.2, 1.3
- Appendix 1.3.2
- Sections 2.1.1, 2.1.2, 2.3, 2.4, 2.6, 2.7, 2.10
- Tables 2.1 and 2.2
- Figures 2.1, 2.4, 2.9, 2.10
- Appendix 2.10.5, 2.10.6
- Sections 3.1, 3.2, 3.3, 3.4, 3.5, 3.7
- Figures 3.1, 3.2
- Tables 3.1, 3.3, 3.4, 3.6, 3.7
- Appendices 3.7.1, 3.7.2
- Section 5.1, 5.4
- Figure 5.1
- Figure 7.1
- Section 8.1
- Appendix 9.3.2

4. The information has been held in confidence by MDS Nordion, and any disclosure thereof for developmental purposes, has been accompanied by a confidentiality agreement protecting the trade secrets contained herein.
5. The information has been transmitted to and received by the Nuclear Regulatory Commission in the United States in confidence.
6. This information is not available in public sources.
7. The information contained in this affidavit is to the best of my knowledge true and correct.

Sworn before me this 20th day of Feb, 2003 in the City of Ottawa, Ontario, Canada.


Richard G. Stacey
Notary Public in and
for the Province of Ontario, Canada


per: David McInnes
V.P., Corporate Communications
MDS Nordion, a division of MDS (Canada) Inc.